| Drug Name | Direct Acting Antivirals (DAAs) |
|---|---|
| Drug Class |
Anti-viral
|
| Risk minimization type |
Safety communication
|
| Specialty (Theraputic area) |
Infectious disease
|
| Risk |
Risk of hepatitis B reactivation |
| safety communication |
|